Literature DB >> 12871839

Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram.

Piotr Popik1, Ewa Kozela, Martyna Krawczyk.   

Abstract

1. Epidemiological and clinical observations suggest the involvement of nicotinic acetylcholine receptors (nAChRs) in depressive illness. Nonetheless, there is no clearcut evidence that nicotine and/or nAChR antagonists produce an antidepressant effect. 2. In the tail-suspension test (C57/Bl male mice), nicotine (0.8-1.2 mg kg(-1) s.c. or i.p.) given 15-60 min before the measurement exerted no effect on immobility. 3. Given 30 min before the measurement, citalopram (2 mg kg(-1)) produced a slight decrease in immobility; coadministration of nicotine (0.8 mg kg(-1), 15 but not 40 min before the test) to citalopram-treated mice resulted in a robust decrease in immobility. Imipramine (4 mg kg(-1)) did not affect immobility, but given in combination with 0.8 mg kg(-1) of nicotine (15 but not 40 min before the test), a decrease in immobility was observed. Nicotine (0.8 and 1.2 mg kg(-1)) also produced an enhancement in the anti-immobility effect of imipramine (20 mg kg(-1)). 4. We further investigated if nAChR antagonists would influence the antidepressant-like effects of imipramine and citalopram. Unexpectedly, mecamylamine (1-2.5 mg kg(-1)) and dihydro-beta-erythroidine (2 mg kg(-1)) potentiated the antidepressant-like effect of imipramine (4-20 mg kg(-1)). Mecamylamine (2.5 mg kg(-1)) but not dihydro-beta-erythroidine also increased the antidepressant-like effect produced by 2 mg kg(-1) of citalopram. 5. The interaction between nAChR antagonists and antidepressants appeared synergistic. 6. Neither nAChR ligands, antidepressants nor combinations of the two, affected locomotor activity. 7. The present results demonstrate an unexpected interaction between nAChR ligands and imipramine and citalopram in the tail-suspension test.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871839      PMCID: PMC1573951          DOI: 10.1038/sj.bjp.0705359

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid.

Authors:  E Toth; H Sershen; A Hashim; E S Vizi; A Lajtha
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

Review 2.  The paradox of nicotinic acetylcholine receptor upregulation by nicotine.

Authors:  S Wonnacott
Journal:  Trends Pharmacol Sci       Date:  1990-06       Impact factor: 14.819

3.  Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine.

Authors:  B Rana; S O McMorn; H L Reeve; C N Wyatt; P F Vaughan; C Peers
Journal:  Eur J Pharmacol       Date:  1993-12-07       Impact factor: 4.432

Review 4.  Presynaptic ionotropic receptors.

Authors:  D S McGehee; L W Role
Journal:  Curr Opin Neurobiol       Date:  1996-06       Impact factor: 6.627

5.  Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits.

Authors:  S C Harvey; F N Maddox; C W Luetje
Journal:  J Neurochem       Date:  1996-11       Impact factor: 5.372

6.  Investigation of mechanisms linking depressed mood to nicotine dependence.

Authors:  C Lerman; J Audrain; C T Orleans; R Boyd; K Gold; D Main; N Caporaso
Journal:  Addict Behav       Date:  1996 Jan-Feb       Impact factor: 3.913

7.  Bupropion treatment of depression to assist smoking cessation.

Authors:  H I Lief
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

8.  Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement.

Authors:  T Kinnunen; K Doherty; F S Militello; A J Garvey
Journal:  J Consult Clin Psychol       Date:  1996-08

9.  The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist.

Authors:  W A Varanda; Y Aracava; S M Sherby; W G VanMeter; M E Eldefrawi; E X Albuquerque
Journal:  Mol Pharmacol       Date:  1985-08       Impact factor: 4.436

10.  Effects of systemic nicotine on serotonin release in rat brain.

Authors:  E B Ribeiro; R L Bettiker; M Bogdanov; R J Wurtman
Journal:  Brain Res       Date:  1993-09-10       Impact factor: 3.252

View more
  25 in total

1.  Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice.

Authors:  Yann S Mineur; Tenna N Mose; Sam Blakeman; Marina R Picciotto
Journal:  Br J Pharmacol       Date:  2017-04-08       Impact factor: 8.739

Review 2.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

Review 3.  Examining antidepressant drug response by smoking status: why is it important and how often is it done?

Authors:  Andrea H Weinberger; Sherry A McKee; Marina R Picciotto; Carolyn M Mazure
Journal:  J Psychopharmacol       Date:  2010-12-17       Impact factor: 4.153

Review 4.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

5.  Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests.

Authors:  Arya Haj-Mirzaian; Nastaran Kordjazy; Arvin Haj-Mirzaian; Sattar Ostadhadi; Mehdi Ghasemi; Shayan Amiri; Mehrdad Faizi; AhmadReza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2015-07-15       Impact factor: 4.530

Review 6.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

7.  The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice.

Authors:  R L Rabenstein; B J Caldarone; M R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

8.  Behavioral effects of nicotinic antagonist mecamylamine in a rat model of depression: prefrontal cortex level of BDNF protein and monoaminergic neurotransmitters.

Authors:  Sawsan Aboul-Fotouh
Journal:  Psychopharmacology (Berl)       Date:  2014-10-15       Impact factor: 4.530

Review 9.  Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression.

Authors:  Jason A Gandelman; Paul Newhouse; Warren D Taylor
Journal:  Neurosci Biobehav Rev       Date:  2017-08-30       Impact factor: 8.989

Review 10.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.